Content area
Full Text
The latest frontier of biotech, a DNA approach to drugs called "personal medicine," may provide the next frontier for healthcare M&A.
The human genome project first identified how genes responded to different drugs. Out of that grew pharmacogenomics, a subset of personalized medicine that looks at a patient's genetic marker. With such information, medicine can be personalized with drug companies to customize a drug to a particular patient population, or it can even be designed for a patient population based on gene type or DNA.
"There is a business opportunity on the diagnostic side and on the therapeutic side to design medicines that are specific to individuals, and that is called pharmacogenomics." said the global...